Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751987 | 0.75 | HSD17B10 (0.58) | HSD17B10ALDH1A1CCNE2CDK4CCND1 | |
| SCHEMBL11132128 | 0.74 | NPC1 (0.52) | ALDH1A1NPC1RAB9AKDM4EMAPT | |
| SCHEMBL28435414 | 0.74 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTHTTMEN1 | |
| SCHEMBL28600460 | 0.74 | CHRM3 (0.50) | ALDH1A1CHRM3 | |
| SCHEMBL14198623 | 0.72 | KDM1A (0.39) | HSD17B10NPC1RAB9AKDM4EHDAC3 | |
| SCHEMBL5084657 | 0.71 | NPC1 (0.55) | HSD17B10ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL15259585 | 0.70 | KDM4E (0.57) | ALDH1A1KDM4EMAPTPKMHTT | |
| SCHEMBL25356036 | 0.70 | NPC1 (0.77) | HSD17B10ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL30752014 | 0.69 | HSD17B10 (0.51) | HSD17B10NPC1RAB9ACCNE2CCNE1 | |
| SCHEMBL27718025 | 0.69 | CHRM2 (0.46) | HSD17B10ALDH1A1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203415-B1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINES | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-8148375-B2 | (Cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-8148375-B2 | (Cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20100261644-A1 | (CYCLOPROPYLPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261644-A1 | (CYCLOPROPYLPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| CN-101796018-A | (cyclopropylphenyl) phenyloxamides, their production and their use as medicaments | SANOFI AVENTIS | 2010-08-04 | — | — | CN | disclosed |
| CN-101796018-A | (cyclopropylphenyl) phenyloxamides, their production and their use as medicaments | SANOFI AVENTIS | 2010-08-04 | — | — | CN | disclosed |
| EP-2203415-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | Sanofi-Aventis (FR) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203415-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | Sanofi-Aventis (FR) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009039942-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009039942-A1 | (CYCLOPROPYL-PHENYL)-PHENYL-OXALAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261644-A1 | (CYCLOPROPYLPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME AS A MEDICAMENT | PPOX, OAT, PNPO | HSD17B10 1482/4885ALDH1A1 782/4885NPC1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.